CANCER TREATMENT METHOD
Invented is a method of treating cancer in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a TPO cell cycle activator and a chemotherapeutic agent to such mammal.
1 . A method of treating a cancer which is known to enter noncycling cell phases in a mammal in need thereof which comprises the in vivo administration of an effective amount of
a) at least one TPO cell cycle activator, and
b) at least one chemotherapeutic agent.
2 . The method of claim 1 wherein the mammal is a human.
3 . The method of claim 2 wherein the cancer is selected from:
Lymphoblastic T cell leukemia, Chronic myelogenous leukemia, Chronic lymphocytic leukemia, Hairy-cell leukemia, acute lymphoblastic leukemia, Chronic neutrophilic leukemia, Acute lymphoblastic T cell leukemia, Plasmacytoma, Immunoblastic large cell leukemia, Mantle cell leukemia, Megakaryoblastic leukemia, multiple myeloma, acute myelogenous leukemia (AML), promyelocytic leukemia, acute megakaryocytic leukemia, and Erythroleukemia.
4 . The method of claim 2 wherein the TPO cell cycle activator is AMG531.
5 . The method of claim 3 wherein the TPO cell cycle activator is AMG531.
6 . The method of claim 2 wherein the chemotherapeutic agent is selected from: gemcitabine, carboplatin, cisplatin, cytarabine, thalidomide, lenolidomide and decitabine.
7 . The method of claim 3 wherein the chemotherapeutic agent is selected from: gemcitabine, carboplatin, cisplatin, cytarabine, thalidomide, lenolidomide and decitabine.
8 . The method of claim 4 wherein the chemotherapeutic agent is selected from: gemcitabine, carboplatin, cisplatin, cytarabine, thalidomide, lenolidomide and decitabine.
9 . The method of claim 5 wherein the chemotherapeutic agent is selected from: gemcitabine, carboplatin, cisplatin, cytarabine, thalidomide, lenolidomide and decitabine.